Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms
- PMID: 11004015
- DOI: 10.1152/ajpregu.2000.279.4.R1449
Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms
Abstract
The incretin glucagon-like peptide-1 (GLP-1)-(7---36) amide is an important factor in prandial glucose homeostasis. Findings that GLP-1 is rapidly inactivated led to the hypothesis that the target of GLP-1 is close to the site of release. To investigate whether the target tissue is located in the hepatoportal system, we administered GLP-1 with glucose into the portal vein of rats and compared this with peripheral GLP-1 administration (jugular vein) and studied the effects of blockers of the nervous system. Portal GLP-1 augmented the insulin response to a portal glucose bolus by 81% (P < 0.01) and markedly improved the glucose disposal rate (P < 0.05). Peripheral administration of GLP-1 produced a similar augmentation of the insulin response (88%) and of the glucose disposal rate. However, only the effect of portal GLP-1 on insulin secretion was blocked by the ganglionic blocker chlorisondamine. The data suggest that prandial beta-cell stimulation by GLP-1 is evoked via a neural reflex triggered in the hepatoportal system. Because absorbed nutrients and GLP-1 first appear in the portal system, this mechanism may constitute a major pathway of GLP-1 action during meals.
Similar articles
-
Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor.Diabetes. 2001 Aug;50(8):1720-8. doi: 10.2337/diabetes.50.8.1720. Diabetes. 2001. PMID: 11473030
-
Rapid hepatic metabolism blunts the endocrine action of portally infused GLP-1 in male rats.Am J Physiol Endocrinol Metab. 2020 Feb 1;318(2):E189-E197. doi: 10.1152/ajpendo.00298.2019. Epub 2019 Nov 19. Am J Physiol Endocrinol Metab. 2020. PMID: 31743041 Free PMC article.
-
Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.Diabetes. 1996 Nov;45(11):1524-30. doi: 10.2337/diab.45.11.1524. Diabetes. 1996. PMID: 8866556
-
[The entero-insular axis: the new incretin candidate glucagon-like peptide-1(7-36)amide (GLP-1(7-36))amide].Z Gastroenterol. 1988 Nov;26(11):715-9. Z Gastroenterol. 1988. PMID: 2849249 Review. German.
-
The incretins: a link between nutrients and well-being.Br J Nutr. 2005 Apr;93 Suppl 1:S147-56. doi: 10.1079/bjn20041340. Br J Nutr. 2005. PMID: 15877888 Review.
Cited by
-
Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors.Diabetologia. 2005 Apr;48(4):612-5. doi: 10.1007/s00125-005-1705-7. Epub 2005 Mar 10. Diabetologia. 2005. PMID: 15759106 No abstract available.
-
Novel glucagon-like peptide-1 analog delivered orally reduces postprandial glucose excursions in porcine and canine models.J Diabetes Sci Technol. 2010 Nov 1;4(6):1516-23. doi: 10.1177/193229681000400629. J Diabetes Sci Technol. 2010. PMID: 21129350 Free PMC article.
-
Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects.Obes Surg. 2012 Jul;22(7):1084-96. doi: 10.1007/s11695-012-0621-4. Obes Surg. 2012. PMID: 22359255
-
Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass.Diabetologia. 2012 Jul;55(7):1890-901. doi: 10.1007/s00125-012-2556-7. Epub 2012 Apr 27. Diabetologia. 2012. PMID: 22538359 Review.
-
Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms.Endocrinology. 2009 Mar;150(3):1174-81. doi: 10.1210/en.2008-1221. Epub 2008 Oct 23. Endocrinology. 2009. PMID: 18948395 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical